Physician profile
Sarat C Susarla
NPI 1356515829
$194,144.49
in general payments reported to CMS, 2019-2025
29 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80K · 2020: $10K · 2021: $28K · 2022: $17K · 2023: $16K · 2024: $21K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $7,783 · Travel and Lodging: $5,602 · Food and Beverage: $5,200 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,674 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,476.95 |
| Consulting Fee | $7,783.45 |
| Travel and Lodging | $5,601.62 |
| Food and Beverage | $5,199.53 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,674.00 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $81,349.86 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $51,686.59 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $35,039.40 | 2019-2025 | Fasenra, Tezspire |
| Harmony Biosciences LLC | $9,829.76 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $6,999.04 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $6,548.33 | 2021 | |
| Inspire Medical Systems, INC. | $896.96 | 2021-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $356.37 | 2023-2025 | Lumryz |
| Glaxosmithkline, LLC. | $352.54 | 2019-2025 | Nucala |
| Philips North America LLC | $152.42 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Organon LLC | $124.40 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $122.32 | 2021 | |
| Baxter Healthcare | $97.50 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $96.24 | 2019-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.85 | 2019-2023 | Spiriva Respimat |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $59.99 | 2025 | Sunosi |
| Pharming Healthcare, INC. | $52.91 | 2024-2025 | Ruconest |
| Advanced Respiratory, INC | $46.91 | 2019 | |
| Corium, LLC | $34.75 | 2023 | Azstarys |
| Resmed Corp | $33.13 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $25.24 | 2019 | |
| Sobi, INC | $22.27 | 2021 | |
| Collegium Pharmaceutical, INC. | $21.36 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $18.94 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.83 | 2025 | Alvesco |
| Supernus Pharmaceuticals, INC. | $17.59 | 2023 | Qelbree |
| Amgen INC. | $17.13 | 2022 | |
| Biogen, INC. | $17.12 | 2023 | Spinraza |
| Arbor Pharmaceuticals, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarat Susarla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.